Histopathology of MPGN and C3 glomerulopathies

Nature Reviews Nephrology

Volumn 11, Issue 1, 2015, Pages 14-22

  Cook, H Terence ^a   Pickering, Matthew C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; ELECTRON MICROSCOPY; GENE MUTATION; GLOMERULOPATHY; GLOMERULUS; GLOMERULUS CAPILLARY; HUMAN; IMMUNE COMPLEX DEPOSITION; INFECTION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE I; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE II; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE III; MESANGIUM; MORPHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CLASSIFICATION; GLOMERULONEPHRITIS; IMMUNOLOGY; KIDNEY; PATHOLOGY;

COMPLEMENT C3; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KIDNEY;

EID: 84927175264     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.217     Document Type: Review

References (60)

1. Taal, M. W. et al. (eds.) Brenner and Rector's The Kidney (Elsevier, 2012).
2. Fakhouri, F. et al. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 6, 494-499 (2010).
3. Churg, J., Bernstein, J. & Glassock R. J. Renal Disease: Classification and Atlas of Glomerular Diseases 2nd edn (Igaku-Shoin, 1995).
4. Jones, D. B. Glomerulonephritis. Am. J. Pathol. 29, 33-51 (1953).
5. Porter, K. A. et al. Human renal transplants. I. Glomerular changes. Lab. Invest. 16, 153-181 (1967).
6. Husain, S. & Sis, B. Advances in the understanding of transplant glomerulopathy. Am. J. Kidney Dis. 62, 352-363 (2013).
7. Levy, M. et al. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin. Immunol. Immunopathol. 10, 477-492 (1978).
8. Berger, J. & Galle, P. Depots dense au sein des membranes basales du rein: etude en microscopies optique et electronique [French]. Presse Med. 71, 2351-2354 (1963).
9. Habib, R. et al. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 7, 204-215 (1975).
10. Appel, G. B. et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J. Am. Soc. Nephrol. 16, 1392-1403 (2005).
11. Smith, R. J. et al. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 18, 2447-2456 (2007).
12. Burkholder, P. M., Marchand, A. & Krueger, R. P. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab. Invest. 23, 459-479 (1970).
13. Strife, C. F., McEnery, P. T., McAdams, A. J. & West, C. D. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin. Nephrol. 7, 65-72 (1977).
14. Anders, D., Agricola, B., Sippel, M. & Thoenes, W. Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch. A. Pathol. Anat. Histol. 376, 1-19 (1977).
15. Sethi, S. & Fervenza, F. C. Membranoproliferative glomerulonephritis-a new look at an old entity. N. Engl. J. Med. 366, 1119-1131 (2012).
16. Sethi, S. & Fervenza, F. C. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 31, 341-348 (2011).
17. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241-250 (2004).
18. Alpers, C. E. & Smith, K. D. Cryoglobulinemia and renal disease. Curr. Opin. Nephrol. Hypertens. 17, 243-249 (2008).
19. Kawamura, T. et al. Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s in Japan. Clin. Exp. Nephrol. 17, 248-254 (2013).
20. Johnson, R. J. et al. Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide. Am. J. Kidney Dis. 42, 575-581 (2003).
21. Nasr, S. H. et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J. Am. Soc. Nephrol. 20, 2055-2064 (2009).
22. Nasr, S. H. et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin. J. Am. Soc. Nephrol. 6, 775-784 (2011).
23. Rosenstock, J. L. et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int. 63, 1450-1461 (2003).
24. Fervenza, F. C., Sethi, S. & Glassock, R. J. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol. Dial. Transplant. 27, 4288-4294 (2012).
25. Habib, R. et al. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 7, 204-215 (1975).
26. Jenis, E. H. et al. Glomerulonephritis with basement membrane dense deposits. Arch. Pathol. 97, 84-91 (1974).
27. Pickering, M. C. et al. C3 glomerulopathy: consensus report. Kidney Int. 84, 1079-1089 (2013).
28. Nasr, S. H. et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 4, 22-32 (2009).
29. Walker, P. D., Ferrario, F., Joh, K. & Bonsib S. M. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod. Pathol. 20, 605-616 (2007).
30. Herlitz, L. C. et al. Pathology after eculizumab in dense deposit disease and C3 GN. J. Am. Soc. Nephrol. 23, 1229-1237 (2012).
31. Servais, A. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454-464 (2012).
32. Medjeral-Thomas, N. R. et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin. J. Am. Soc. Nephrol. 9, 46-53 (2014).
33. Hou, J. et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 85, 450-456 (2014).
34. West, C. D. Nephritic factors predispose to chronic glomerulonephritis. Am. J. Kidney Dis. 24, 956-963 (1994).
35. Vallota, E. H. et al. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J. Exp. Med. 139, 1249-1261 (1974).
36. Schwertz, R. et al. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr. Allergy Immunol. 12, 166-172 (2001).
37. Lu, D. F. et al. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr. Nephrol. 27, 773-781 (2012).
38. Cameron, J. S. et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am. J. Med. 74, 175-192 (1983).
39. Bennett, W. M. et al. Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. Am. J. Kidney Dis. 13, 469-476 (1989).
40. Little, M. A. et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 69, 504-511 (2006).
41. Pickering, M. C. & Cook, H. T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin. Exp. Immunol. 151, 210-230 (2008).
42. Licht, C. et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 70, 42-50 (2006).
43. Jokiranta, T. S. et al. Nephritogenic λ light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163, 4590-4596 (1999).
44. Martinez-Barricarte, R. et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 120, 3702-3712 (2010).
45. Athanasiou, Y. et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin. J. Am. Soc. Nephrol. 6, 1436-1446 (2011).
46. Deltas, C. et al. C3 glomerulonephritis/CFHR5 nephropathy is an endemic disease in Cyprus: clinical and molecular findings in 21 families. Adv. Exp. Med. Biol. 734, 189-196 (2013).
47. Vernon, K. A. et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am. J. Transplant. 11, 152-155 (2011).
48. Tortajada, A. et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J. Clin. Invest. 123, 2434-2446 (2013).
49. Gale, D. P. et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376, 794-801 (2010).
50. Medjeral-Thomas, N. et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int. 85, 933-937 (2014).
51. Neary, J. et al. Familial membranoproliferative glomerulonephritis type III. Am. J. Kidney Dis. 40, E1 (2002).
52. Malik, T. H. et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J. Am. Soc. Nephrol. 23, 1155-1160 (2012).
53. Neary, J. J. et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J. Am. Soc. Nephrol. 13, 2052-2057 (2002).
54. Zhang, Y. et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin. J. Am. Soc. Nephrol. 7, 265-274 (2012).
55. Abrera-Abeleda, M. A. et al. Allelic variants of complement genes associated with dense deposit disease. J. Am. Soc. Nephrol. 22, 1551-1559 (2011).
56. Sethi, S. et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 83, 293-299 (2013).
57. Sandhu, G. et al. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am. J. Kidney Dis. 60, 1039-1043 (2012).
58. Little, M. A., Dupont, P., Campbell, E., Dorman, A. & Walshe, J. J. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 69, 504-511 (2006).
59. Braun, M. C. et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J. Am. Soc. Nephrol. 16, 2225-2233 (2005).
60. Zand, L. et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J. Am. Soc. Nephrol. 25, 1110-1117 (2014).